查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球心臟生物標誌物市場-2022-2029
市場調查報告書
商品編碼
1146419

全球心臟生物標誌物市場-2022-2029

Global Cardiac Biomarkers Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期間（2022-2029 年），心臟生物標誌物的市場規模預計將以 10.5% 的複合年增長率增長。

心臟生物標誌物是心臟受損或受壓時釋放到血液中的生物分子。此類生物標誌物的識別和估計有助於診斷急性冠狀動脈症候群 (ACS)、心臟缺血或其他與心臟血流受損相關的疾病。

市場動態

不斷上升的心髒病人口、人口老齡化和市場開發正在推動全球心臟生物標誌物市場的增長。

心血管疾病發病率的上升和老年人口的增加正在推動全球心臟生物標誌物市場的增長。

由於心血管疾病病例的增加，預計市場在預測期內將擴大。根據英國心臟基金會的數據，2020 年將有超過 168,319 人死於心血管疾病。由於世界上老年人口的增加和現代生活方式的採用，心血管病例的數量正在增加。根據世界衛生組織數據，2020年60歲及以上人口將超過10億，預計到2050年將達到21億。此外，煙草每年在全世界造成 800 萬人死亡。在這 800 萬人中，約 700 萬人是由於直接使用煙草造成的，約 120 萬人是由於非吸煙者接觸二手煙造成的。因此，從上述數據來看，心血管病例和老年人口的增加預計將推動全球心血管生物標誌物市場的增長。

缺乏特異性以及對更靈敏的心臟生物標誌物分析系統的需求阻礙了全球心臟生物標誌物市場的增長。

然而，對非特異性和更敏感的心臟生物標誌物分析系統的需求是限制全球心臟生物標誌物市場增長的一個因素。根據美國臨床化學協會 (AACC) 的說法，將心臟生物標誌物用作即時檢測 (POCT) 需要高度敏感的診斷工具，因為 POCT 無法區分肌鈣蛋白等低水平的心臟生物標誌物。這是。此外，由於肌鈣蛋白濃度升高需要幾個小時，因此在需要快速決策的情況下不能採用這種診斷方法。

COVID-19 的影響

由於在大流行期間增加使用心臟生物標誌物以降低患心髒病的風險，COVID-19 大流行對全球心臟生物標誌物市場產生了積極影響。根據 NCBI，在 2021 年，複雜的 COVID-19 病例顯示與不良疾病結果相關的心臟生物標誌物升高。因此，在大流行期間，心臟生物標誌物的銷售額相對於嚴重的 COVID-19 病例有所上升，這對全球心臟生物標誌物市場產生了積極影響。

細分分析

預計在預測期間（2022-2029 年），床旁檢測的需求量很大。

預計在預測期內（2022-2029 年），床旁檢測將主導全球心臟生物標誌物市場。即時檢測是在患者處或附近進行的檢測。重要的是，這是在實驗室之外進行的測試。與傳統實驗室測試相比，即時測試可以在更短的時間內完成，並對患者護理產生直接影響。床旁檢測通過為醫生提供有關患者狀況的即時詳細資訊，改善了患者的體驗，提供更高質量的護理。

即時檢測的優勢正在推動其在全球心臟生物標誌物市場的主導地位。例如，即時結果可增強臨床工作流程並提供運營和財務收益。與傳統的實驗室測試相比，即時檢測對患者來說更方便，並提高了患者的滿意度。此外，醫療點支持對有心血管疾病 (CVD) 風險的人進行健康檢查，增加患者檢測並有助於降低心血管死亡率。根據世界衛生組織 (WHO) 的數據，心髒病發作和中風導致的過早死亡中有 80% 是可以預防的。總之，在預測期內，護理點預計將主導全球心臟生物標誌物市場。

區域分析

預計全球心臟生物標誌物市場將由北美主導。

北美主導著全球心臟生物標誌物市場。據評估，它在預測期內（2022-2029 年）將保持巨大的市場規模。例如，根據 CDC 的數據，到 2020 年，每 34 秒就有一名美國人死於心血管疾病，導致超過 697,000 人死亡。此外，Abbott Laboratories、Beckman Coulter、Roche Diagnostics Ltd.、Becton Dickinson & Company、Bio-Rad Laboratories、Thermo Fisher Scientific 等大多數主要市場參與者都在場，在全球心臟生物標誌物市場佔有很大份額通過各種市場策略，總部位於美國，這確保了北美在全球心臟生物標誌物市場的主導地位。例如，2021 年 4 月，羅氏（Roche）宣布了兩個關鍵心臟生物標誌物的新系列生物標誌物，即高敏心肌肌鈣蛋白 T（cTnT-hs）和 N 端腦利鈉□前體測試（NT-proBNP），使用 Elecsys技術。提出了所需的應用。同樣在 2021 年 7 月，Beckman Coulter 與 Quidel Corporation 簽訂了最終協議，以獲取製造、分銷和銷售用於 Beckman Coulter 分析儀的 BNP 檢測的所有權利。

競爭格局

Thermo Fisher 是一家美國公司，成立於 1956 年。它擁有 Thermo Scientific、Applied Biosystems、Invitrogen、Fisher Scientific、Unity Lab Services、Patheon 和 PPD 等行業領先品牌，是科學服務領域的全球領導者，年收入約為 400 億美元。

產品組合

Thermo Fisher 的心臟生物標誌物產品組合包括 Thermo Scientific MAS CardioImmune XL Controls。 Thermo Scientific MAS CardioImmune XL Controls：即用型液體測量多分析物對照品，用於監測血清心臟標誌物測定。這些質控品也以合適的 Vista 小瓶形式提供。

全球心臟生物標誌物市場報告提供對 40 多個 市場數據表、45 多個圖表和 200 頁（大約）的訪問。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 心腦血管疾病增加
      • 老年人口增加
    • 抑制因素
      • 缺乏特異性
      • 需要更靈敏的心臟生物標誌物分析系統
      • 嚴格的規定
    • 商機
    • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章心臟生物標誌物測試

  • 肌鈣蛋白（I 或 T）
  • 肌酸激□ (CK)
  • 肌紅蛋白
  • 半乳糖凝集素3
  • HS-CRP
  • BNP（或 NT-proBNP）

第 8 章適應症

  • 急性冠狀動脈症候群
  • 充血性心力衰竭
  • 心肌梗塞 (MI)
  • 心絞痛
  • 其他

第 9 章最終用戶

  • 實驗室檢查
  • 即時檢測

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • Thermo Fisher Scientific
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Abbott Laboratories
  • Beckman Coulter
  • Roche Diagnostics Corporation
  • Becton Dickinson And Co.
  • Bio-Rad Laboratories
  • BioMerieux
  • Siemens Healthcare
  • LumiraDx
  • Randox laboratories

第 13 章 DataM

簡介目錄
Product Code: DMCD256

Market Overview

Cardiac Biomarkers Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 10.5% during the forecast period (2022-2029).

Cardiac biomarkers are biological molecules released into the blood as the heart is damaged or under stress. Identifying and estimating such biomarkers help diagnose acute coronary syndrome (ACS) and cardiac ischemia or other conditions associated with impaired blood flow to the heart.

Market Dynamics

The rising heart disease cases, growing geriatric population and market developments fuel the growth of the global cardiac biomarkers market.

The growing incidences of cardiovascular disease and the geriatric population propel the global cardiac biomarkers market growth.

The growing cases of cardiovascular diseases are anticipated to expand the market over the forecast period. According to the British Heart Foundation, in 2020, over 168,319 deaths were caused by cardiovascular diseases. Since the global geriatric population is growing at an increased rate, and the adoption of modern lifestyles are contributing factors to the growing incidences of cardiovascular cases. According to the world health organization data, in 2020, over 1 billion people were aged 60 and above, which is predicted to be 2.1 billion by 2050. Furthermore, annually 8 million people are dead due to tobacco consumption worldwide. Out of these 8 million, about 7 million are due to the direct use of tobacco, and around 1.2 million are because non-smokers are exposed to secondhand smoke. Thus, with the data mentioned earlier, the growing cardiovascular cases and geriatric population will drive the global cardiovascular biomarkers market growth.

The absence of specificity and the necessity of a more sensitive cardiac biomarker analysis system hinder the global cardiac biomarkers market growth.

However, the absence of specificity and the necessity of a more sensitive cardiac biomarker analysis system is a major restraint for the global cardiac biomarker market growth. According to American Association for Clinical Chemistry (AACC), using cardiac biomarkers as point-of-care testing (POCT) needs a high-sensitivity diagnostic tool since POCT cannot identify low levels of a cardiac biomarker such as troponin. Since it takes several hours to increase troponin levels for the system to detect, such a diagnostic method cannot be employed in rapid decision-requiring situations.

COVID-19 Impact

There was a positive impact of the COVID-19 pandemic on the global cardiac biomarker market since the use of cardiac biomarkers increased during the pandemic to reduce the risk of cardiac diseases. According to the NCBI, in 2021, complicated cases of COVID-19 exhibited raised cardiac biomarkers associated with adverse disease outcomes. Therefore, the sales of cardiac biomarkers were elevated for severe COVID-19 cases during the pandemic, positively impacting the global cardiac biomarker market.

Segment Analysis

Point-of-care testing is predicted to have a high demand during the forecast period (2022-2029).

Point-of-care testing is expected to dominate the global cardiac biomarkers market during the forecast period (2022-2029). Point-of-care testing is a test conducted at or near the site of the patient. Importantly it is a laboratory test performed outside of the laboratory setting. Point-of-care testing gives a quicker completion time than traditional laboratory testing, with the potential for immediate impact on patient care. Point-of-care testing enhances patient experience with a higher quality of care via delivering rapid details to the physicians regarding the patient's condition.

The benefits offered by point-of-care testing fuel this segment's dominance over the global cardiac biomarkers market. For instance, the results are available immediately and practice workflow is enhanced, resulting in operational and economic benefits. Point-of-care testing is more convenient than conventional laboratory testing for patients, which has improved patient satisfaction. Furthermore, point of care can support health screenings in those at risk of cardiovascular disease (CVD) and enhance patient adherence with testing frequency, benefitting in reducing cardiovascular mortality. Since 80% of premature deaths from heart attack and stroke are avoidable, as per the World Health Organization. Thus, from the data mentioned, it is anticipated that the point of care will dominate the global cardiac biomarkers market throughout the forecast period.

Geographical Analysis

North America is predicted to command the global Cardiac Biomarkers market.

North America dominated the global cardiac biomarkers market. It is evaluated to hold a significant market size over the forecast period (2022-2029). As there are a high number of cardiovascular cases, for example, according to the CDC, in 2020, a U.S. American died every 34 seconds of cardiovascular disease, causing over 697,000 deaths. Furthermore, the presence of most of the key market players like Abbott Laboratories, Beckman Coulter, Roche Diagnostics Corporation, Becton Dickinson And Co., Bio-Rad Laboratories, and Thermo Fisher Scientific, holding a large share of the global cardiac biomarkers market through various market tactics are based in the United States ensuring the dominance of North America over the global cardiac biomarkers market. For instance, in April 2021, Roche introduced a series of five new intended applications for two key cardiac biomarkers using the Elecsys technology, a high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). Also, in JULY 2021, Beckman Coulter formed a definitive agreement with Quidel Corporation to obtain all rights associated with the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers.

Competitive Landscape

The major players operating in the global Cardiac Biomarkers market are Abbott Laboratories, Beckman Coulter, Roche Diagnostics Corporation, Becton Dickinson and Co., Bio-Rad Laboratories, BioMerieux, Siemens Healthcare, LumiraDx, Randox laboratories and Thermo Fisher Scientific. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the cardiac biomarkers market globally. For instance, in June 2022, LumiraDx Limited diversified its portfolio with CE Mark for its D-Dimer and NT-proBNP tests.

Thermo Fisher.

Overview:

Thermo Fisher is a U.S.-based company founded in 1956. It is the world leader in serving science with annual revenue of approx. $40 billion has industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.

Product Portfolio:

The product portfolio of Thermo Fisher for cardiac biomarkers contains Thermo Scientific MAS CardioImmune XL Controls: Monitor serum cardiac marker test methods with ready-to-use, liquid-assayed multi-analyte Thermo Scientific MAS CardioImmune XL Controls. These controls are also available in a suitable Vista vial format.

The global cardiac biomarkers market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Cases of Cardio-vascular diseases
      • 4.1.1.2. Growing Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. Absence of Specificity
      • 4.1.2.2. The Necessity of a More Sensitive Cardiac Biomarker Analysis System
      • 4.1.2.3. Stringent Regulation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Cardiac Biomarker Tests

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 7.1.2. Market Attractiveness Index, By Cardiac Biomarker Tests
  • 7.2. Troponin (I or T)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Creatine kinase (CK)
  • 7.4. Myoglobin
  • 7.5. Galectin-3
  • 7.6. HS-CRP
  • 7.7. BNP (or NT-proBNP)

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Acute Coronary Syndrome
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Congestive Heart Failure
  • 8.4. Myocardial infarction (MI)
  • 8.5. Angina
  • 8.6. Other

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Laboratory Testing
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Point of Care Testing

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Thermo Fisher Scientific
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Abbott Laboratories
  • 12.3. Beckman Coulter
  • 12.4. Roche Diagnostics Corporation
  • 12.5. Becton Dickinson And Co.
  • 12.6. Bio-Rad Laboratories
  • 12.7. BioMerieux
  • 12.8. Siemens Healthcare
  • 12.9. LumiraDx
  • 12.10. Randox laboratories

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us